Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio
- Written by PR Newswire
![]() |
- Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs.
- Transaction represents total equity value of approximately $2.5 billion.
SURESNES, France and BRISBANE, Calif., March 7, 2026 /PRNewswire/ -- Servier, an independent...















